Cancer Center, Southern Medical University, Guangzhou 510315, China ; Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou 510315, China ; Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Gastroenterol Res Pract. 2014;2014:498246. doi: 10.1155/2014/498246. Epub 2014 Mar 30.
Purpose. To investigate the expression of TSP50 protein in human gastric cancers and its correlation with clinical/prognostic significance. Methods. Immunohistochemistry (IHC) analysis of TSP50 was performed on a tissue microarray (TMA) containing 334 primary gastric cancers. Western blot was carried out to confirm the expression of TSP50 in gastric cancers. Results. IHC analysis revealed high expression of TSP50 in 57.2% human gastric cancer samples (191 out of 334). However, it was poorly expressed in all of the 20 adjacent nontumor tissues. This was confirmed by western blot, which showed significantly higher levels of TSP50 expression in gastric cancer tissues than adjacent nontumor tissues. A significant association was found between high levels of TSP50 and clinicopathological characteristics including junior age at surgery (P = 0.001), later TNM stage (P = 0.000), and present lymph node metastases (P = 0.003). The survival of gastric cancer patients with high expression of TSP50 was significantly shorter than that of the patients with low levels of TSP50 (P = 0.021). Multivariate Cox regression analysis indicated that TSP50 overexpression was an independent prognostic factor for gastric cancer patients (P = 0.017). Conclusions. Our data demonstrate that elevated TSP50 protein expression could be a potential predictor of poor prognosis in gastric cancer patients.
研究 TSP50 蛋白在人胃癌中的表达及其与临床/预后意义的相关性。
对包含 334 例原发性胃癌的组织微阵列（TMA）进行 TSP50 的免疫组织化学（IHC）分析。Western blot 用于证实胃癌中 TSP50 的表达。
IHC 分析显示，57.2%（191/334）的人类胃癌样本中 TSP50 高表达。然而，在所有 20 例相邻非肿瘤组织中均表达较差。Western blot 证实了这一点，其显示胃癌组织中 TSP50 的表达水平明显高于相邻非肿瘤组织。高水平的 TSP50 与包括手术时年龄较轻（P = 0.001）、较晚的 TNM 分期（P = 0.000）和存在淋巴结转移（P = 0.003）在内的临床病理特征之间存在显著相关性。TSP50 高表达的胃癌患者的生存时间明显短于 TSP50 低表达的患者（P = 0.021）。多变量 Cox 回归分析表明，TSP50 过表达是胃癌患者的独立预后因素（P = 0.017）。
我们的数据表明，TSP50 蛋白表达升高可能是胃癌患者预后不良的潜在预测指标。
